Compare Charles River Laboratories Intl. Inc (CRL) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Weibo Corp — how do they compare? Charles River Laboratories Intl. Inc trades at $286.31 (market cap $13.46B), while Weibo Corp trades at $7.74 (market cap $1.93B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 7× Weibo Corp's market cap, and Weibo Corp pays a 7.75% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | WB | |
|---|---|---|
Market Cap | $13.46B | $1.93B |
Sector | Health | Media |
52-Week High | $282.00 | $12.83 |
52-Week Low | $145.57 | $7.20 |
Enterprise Value | $16.30B | $1.20B |
Dividend Yield | — | 7.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $286.36, up 3.38% today and near its 52-week high of $277.07. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent Q2 2026 results exceeded expectations with EPS of $3.02 versus $2.77 estimate, driving positive sentiment. However, valuation metrics remain elevated with P/E at 684.85 and negative profitability margins.
While technical indicators and analyst consensus (72% buy ratings) support near-term upside, fundamental concerns persist with negative net income margin (-5.96%) and ROE (-7.7%). The stock faces execution risks in maintaining earnings momentum amid competitive pressures. Current price exceeds consensus target of $277.29, suggesting limited near-term upside potential despite positive business inflection.
Weibo (WB) trades at $7.74, down 3.01% in the last session, with a bearish technical signal and recent earnings misses. The stock shows strong fundamentals with a low P/E of 5.5 and robust net income margin of 21.15%, while cash flow trends improved in 2025. Recent news highlights Q2 2026 results anticipation and AI developments, but competitive pressures persist.
The outlook is mixed; valuation metrics suggest undervaluation with analyst support, but earnings volatility and market sentiment risks require caution. Opportunities lie in cash flow strength and balance sheet health, while risks include user engagement challenges and macroeconomic headwinds in the social media sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
